EP300 and neoplasm: Other dual inhibitors (Fig. 8d), such as the BRD4/PARP1 inhibitor ADTL-BPI1901 (128) [164], the BRD4/EZH2 inhibitors YM458 (129) [165], the BRD4/p300 inhibitor XP524 (130) [166], the BRD4/CK2 inhibitor 131 [167], and the BRD4/CDK9 inhibitor 132 also achieve synergistic benefits and overcome tumor resistance by simultaneously inhibiting two separate pathways implicated in the cancer [168].